Oncology

Condition or Disorder	Intervention vs. Control	Outcome	Follow-up Duration	Event Rates %		NNT (95% CI)
				CER	EER
Breast cancer1; Postmenopausal women with breast cancer	Radiotherapy plus tamoxifen vs. tamoxifen alone	Recurrence (both locoregional recurrence and distant metastasis)	10 years	60	47	8 (6 to 13)
Stages II and III breast cancer2	Adjuvant chemotherapy + radiotherapy vs. chemotherapy alone	Locoregional recurrence	10 years	26	5	5 (4 to 6)
Locally advanced prostate cancer3	Radiotherapy + goserelin vs. radiotherapy alone	Death	5 years	28	17	10 (5 to 34)
Acute myeloid leukemia; autologous bone-marrow transplantation after intensive chemotherapy4	Bone-marrow transplantation vs. no further treatment	Relapse	7 years	53	34	5 (3 to 11)
		Relapse or cancer-specific death		57	45	9 (5 to 80)
		Death		49	40	Not significant
Breast cancer; preservation of the intercostobrachial nerve during axillary node clearance5	Preservation vs. sacrifice of the intecostobrachial nerve	Some sensory deficit	3 months	84	63	5 (3 to 24)
Breast cancer6	Radiotherapy plus tamoxifen vs. tamoxifen alone	All recurrences	10 years	60	47	8 (6 to 13)
		Locoregional recurrence with or without distant metastases		35	8	4 (4 to 5)
Node-positive prostate cancer7	Antiandrogen therapy immediately after surgery vs. observation	Death	7.1 years	35	15	5 (3 to 34)
		Death from prostate cancer		31	6.4	4 (3 to 10)
		Any recurrence		82	15	2 (2 to 2)
Prostate cancer8	Pelvic floor re-education program (included education about the anatomy and function of the bladder and pelvic floor, active pelvic-floor muscle exercises and biofeedback) vs. placebo program (information about the origin of their incontinence and placebo electrotherapy applied to the abdomen and thighs, but that could not affect pelvic floor function)	Incontinence rate at 3 months (continence was defined as a loss of ≤ 2g of urine on both the 24-hour and 1-hour pad test	1 year	44	10	3 (2 to 6)
		Incontinence at 1 year		17	4	8 (4 to 72)

References

---

1. Lancet 1999; 353:1641-8 
2. N Engl J Med 1997 Oct 2;337(14):949-55 
3. N Engl J Med 1997 Jul 31;337(5):295-300 
4. Lancet 1998 Mar 7;351(9104):700-8 
5. Br J Surg 1998 Oct;85(10):1443-5 
6. Lancet 1999 May 15;353(9165):1641-8 
7. N Engl J Med. Dec 9, 1999; 341: 1781-8 
8. Lancet. Jan 8 2000; 355: 98-102